FLII and Ewing sarcoma: Furthermore, compared to Ewing sarcoma cells with shRNA knock down of EWS/FLI, wild type Ewing sarcoma cells with the EWS/FLI fusion oncoprotein were significantly more sensitive to SP-2509 treatment (57).